Background: Perinatal asphyxia interferes with neonatal development, resulting in long-term deficits associated with systemic and neurological diseases. Despite the important role of poly (ADP-ribose) polymerase 1 (PARP-1) in the regulation of gene expression and DNA repair, overactivation of PARP-1 in asphyxia-exposed animals worsens the ATP-dependent energetic crisis. Inhibition of PARP-1 offers a therapeutic strategy for diminishing the effects of perinatal asphyxia. Methods: We designed a nanosystem that incorporates a specific siRNA for PARP-1 knockdown. The siRNA was complexed with gold nanorods (AuNR) conjugated to the peptide CLPFFD for brain targeting. Results: The siRNA was efficiently delivered into PC12 cells, resulting in gene silencing. The complex was administered intraperitoneally in vivo to asphyxia-exposed rat pups, and the ability of the AuNR-CLPFFD/siRNA complex to reach the brain was demonstrated. Conclusion: The combination of a nanosystem for delivery and a specific siRNA for gene silencing resulted in effective inhibition of PARP-1 in vivo.
CITATION STYLE
Vio, V., Riveros, A. L., Tapia-Bustos, A., Lespay-Rebolledo, C., Perez-Lobos, R., Muñoz, L., … Kogan, M. J. (2018). Gold nanorods/siRNA complex administration for knockdown of PARP-1: A potential treatment for perinatal asphyxia. International Journal of Nanomedicine, 13, 6839–6854. https://doi.org/10.2147/IJN.S175076
Mendeley helps you to discover research relevant for your work.